|Bid||0.00 x 4000|
|Ask||0.00 x 2900|
|Day's Range||4.30 - 4.42|
|52 Week Range||3.64 - 7.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 8, 2018 - May 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.20|
Inovio Pharmaceuticals (INO) doses the first patient in a phase I/II study, which will evaluate its HIV vaccine Pennvax-GP's ability to bring about remission of HIV.
Inovio Pharmaceuticals, Inc. (INO) today announced that it has dosed its first patient in a Phase 1/2a study designed to evaluate the safety, immunogenicity and clinical efficacy of INO-5401, Inovio’s novel cancer immunotherapy that encodes multiple cancer antigens, plus INO-9012, a T cell activator, in combination with atezolizumab, (F. Hoffman-La Roche Ltd.) a PD-L1 inhibitor, for the treatment of advanced or metastatic bladder cancer. The trial, which is being managed by Inovio, is expected to enroll approximately 85 patients at sites located in the United States and Spain. Dr. J. Joseph Kim, Inovio's President and Chief Executive Officer, said, “We are very encouraged to dose our first patient with the aspiration that we can demonstrate the immense potential of our INO-5401 immunotherapy to treat advanced bladder patients as well as those with other cancers.
Nearly $5 billion in combined annual sales could be on the way from these top vaccines in development.
Inovio Pharmaceuticals, Inc. (INO) announced today that the first participant has been dosed with PENNVAX®-GP in a randomized clinical trial that will evaluate its ability to drive remission of HIV infection. This vaccine widely targets all major HIV strains and the potential to enhance the capacity of the immune system to eliminate or provide life-long control of HIV. This trial is part of a previously reported multi-year $6.95 million grant from the NIH’s National Institute of Allergy and Infectious Diseases (NIAID) to develop a single or combination therapy using Inovio’s PENNVAX-GP with the goal of attaining long-term HIV remission.
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / While it wasn’t the numbers Inovio reported in its second quarter financial report, it was a positive update on its phase 3 Reveal 1 clinical study of VGX-3100 ...
A Q2 update about the progress of a late-stage clinical study provides a nice boost to the clinical-stage biotech stock.
Inovio (INO) delivered earnings and revenue surprises of 77.14% and 1050.54%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Plymouth Meeting, Pennsylvania-based company said it had a loss of 8 cents per share. The drugmaker posted revenue of $24.4 million in the period. In the final minutes of trading on Tuesday, the company's ...
PLYMOUTH MEETING, Pa., Aug. 07, 2018-- Inovio Pharmaceuticals, Inc., a late-stage biotechnology company focused on the development and commercialization of DNA immunotherapies targeted against cancers ...
The consortium and Inovio will test an experimental immunotherapy in patients with HPV-related anal dysplasia or squamous intraepithelial lesions and HIV.
During Inovio's (INO) second-quarter 2018 earnings call, investor focus will remain on the company's progress with its lead candidate VGX-3100.
Inovio Pharmaceuticals, Inc. (INO) today announced that it has entered into a partnership with the AIDS Malignancy Consortium (AMC) to evaluate VGX-3100, Inovio’s immunotherapy for treating HPV-associated precancerous conditions in HIV-positive adult men and women. AMC will fund a Phase 2 clinical trial to evaluate the efficacy of VGX-3100 in adult men and women with human papillomavirus (HPV)-related high-grade anal dysplasia or squamous intraepithelial lesions (ASIL) and HIV.
NEW YORK, Aug. 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Getty ...
Inovio Pharmaceuticals, Inc. (INO) announced today that it will host a conference call and live webcast to report its 2018 second quarter financial results on Tuesday, August 7, 2018 at 4:30 p.m. ET. Inovio is a late-stage biotechnology company focused on the discovery, development, and commercialization of DNA immunotherapies that transform the treatment of cancer and infectious diseases. Inovio’s proprietary platform technology, ASPIRE, applies next-generation antigen sequencing and DNA delivery to activate potent immune responses to targeted diseases.
Today, Sellas Life Sciences (SLS) announced that the FDA has assigned fast-track designation to its lead drug, GPS (galinpepimut-S), which is under development for the treatment of multiple myeloma. On the news, SLS stock spiked more than 11% today.
On Thursday, July 12, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Wednesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Innoviva Inc. (NASDAQ: INVA), Inovio Pharmaceuticals Inc. (NASDAQ: INO), and Insmed Inc. (NASDAQ: INSM).
Inovio Pharmaceuticals, Inc. (INO) today announced positive Phase 1 results of its collaborative vaccine study with INO-4700 (GLS-5300) against MERS (Middle East Respiratory Syndrome). Results for INO-4700, which is being co-developed by Inovio and GeneOne Life Science Inc. (KSE:011000), showed that the drug was well-tolerated and demonstrated overall high levels of antibody responses in roughly 95% of subjects, while also generating broad-based T cell responses in nearly 90% of study participants. The Phase 1, open-label, dose-escalation MERS vaccine trial, in partnership with the Walter Reed Army Institute of Research in Maryland, displayed antibody responses by ELISA in 94% of subjects at week 14 (two weeks post-third dose).
Inovio Pharmaceuticals, Inc. (INO) today announced that it has dosed its first patient as part of its Phase 1/2 immuno-oncology trial in patients with newly diagnosed glioblastoma (GBM). The efficacy trial is designed to evaluate Inovio’s INO-5401 T cell activating immunotherapy encoding multiple antigens expressed by GBM and INO-9012, an immune activator encoding IL-12, in combination with cemiplimab (REGN2810), a PD-1 inhibitor developed by Regeneron Pharmaceuticals. Dr. J. Joseph Kim, Inovio's President and Chief Executive Officer, said, “GBM is a devastating cancer, and malignant glioma has already claimed the lives of Senator Ted Kennedy and Beau Biden, the son of the former Vice President Joe Biden.